Compare Novartis AG (NVS) vs Tidewater Inc (TDW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Tidewater Inc — how do they compare? Novartis AG trades at $142.86 (market cap $268.57B), while Tidewater Inc trades at $86.94 (market cap $4.21B). The key difference: Novartis AG is far larger — about 63.8× Tidewater Inc's market cap, and Novartis AG pays a 3.31% dividend while Tidewater Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novartis AG for 82 Days and Tidewater Inc for 25 Days on average.
| NVS | TDW | |
|---|---|---|
Market Cap | $268.57B | $4.21B |
Volume | 1,532,573 | 590,005 |
Sector | Health | Energy |
52-Week High | $168.62 | $100.61 |
52-Week Low | $121.80 | $47.29 |
Typical Hold Time | 82 Days | 25 Days |
Enterprise Value | $309.89B | $4.25B |
Dividend Yield | 3.31% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $143.28, up 1.77% today, with mixed technical signals showing neutral momentum. The company demonstrates strong fundamentals with $56.67B revenue in 2025, 22.5% net margin, and consistent earnings beats in recent quarters. Recent developments include a significant $7.8B licensing deal with China's Abogen for mRNA therapy, though offset by clinical trial setbacks in ALS drug development and ongoing investor scrutiny of M&A strategy.
Outlook remains cautiously optimistic with analyst consensus target of $146 suggesting modest upside. Key opportunities include pipeline expansion through strategic partnerships, while risks involve clinical trial failures, M&A integration challenges, and patent cliff pressures. The stock presents a balanced risk-reward profile with strong profitability offset by pipeline execution concerns.
Tidewater (TDW) trades at $83.40, up 1.62% on the day, with a bullish technical signal driven by moving averages. Recent earnings showed a Q2 2026 beat but misses in Q1 and Q2 relative to expectations, while the company completed the Wilson Sons Ultratug acquisition in August 2026, signaling growth initiatives. Key financials include a P/E of 17.18 and net income margin of 18.34% for 2025, though 2026 projections indicate lower revenue and profitability.
The outlook is mixed, with analyst consensus leaning toward a buy rating and a price target of $105.50 offering upside potential, but risks include earnings volatility, competitive pressures in the energy sector, and macroeconomic headwinds affecting day rates and utilization.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Tidewater Inc
Tidewater is the leading global provider of offshore support vessels (OSVs) to the energy industry. With the world's largest fleet of platform supply vessels (PSVs) and anchor handling tugs (AHTS), it provides critical logistics and marine support for offshore oil, gas, and renewable energy projects. Following a period of massive strategic consolidation, Tidewater is now focused on maximizing day rates and free cash flow in a supply-constrained market, positioning itself as a primary beneficiary of the multi-year offshore upcycle.
Read more on TDW →
